Registration Speakers Agenda Attendees Overview WSGR website

In the event that you were unable to attend, audio recordings are available for most of the sessions. Please click on the Click here to play audio icon next to the panel titles.

2016 Conference Agenda

Thursday June 23, 2016
Sharon Heights Golf and Country Club
2900 Sand Hill Road
Menlo Park, CA

6:00 – 9:00 p.m.

Medical Device Dinner Interview with Mike Buck
Join David Cassak in a conversation with Mike Buck, President of the Medical Products Division of Cardinal Health. Cardinal Health is a diversified provider of high-quality, value-driven medical and pharmaceutical products, services, and solutions that span the continuum of care. Cardinal Health recently acquired Johnson & Johnson’s Cordis business, adding cardiovascular products to their expanding offering of Physician Preference items such as wound management and orthopedics. Learn about Cardinal Health’s solution-driven strategy and the opportunities for companies developing innovative new products that can deliver superior outcomes in a more cost-effective way.


David Cassak, The MedTech Strategist


Mike Buck, Cardinal Health

Friday June 24, 2016

Palace Hotel
2 New Montgomery Street
San Francisco, CA

7:00 – 8:00 a.m.

Conference Registration and Continental Breakfast

8:00 – 8:10 a.m.

Welcome, Casey McGlynn, Wilson Sonsini Goodrich & Rosati

8:10 – 9:10 a.m.

Venture Capital Spotlight
Getting a new medical device company funded is harder today. An ever-shrinking pool of investors interested in early-stage life science investing is one of the hallmarks of the current financing environment. Join us and meet two important new funds which are actively investing in early stage Medtech.


David Cassak, The MedTech Strategist


Joe Cunningham, Santé Ventures


David McIntyre, Apple Tree Partners


9:10 – 9:30 a.m.


9:30 – 10:30 a.m.

Breakout Session 1

Emerging Models for Innovation Click here to play audio
The way we organize, fund and build Medtech companies has changed radically over the last decade.  Join a panel of experienced executives and entrepreneurs to learn about the new emerging models for innovation.  Learn about the methods others are using to identify important new innovation, rapidly build product prototypes and complete early first-in-man cases all in a more intelligent and cost effective manner. 


Scott Murano, Wilson Sonsini Goodrich & Rosati


Ryan McGuinness, TRT Innovation Labs


Fred Toney, Launchpad Digital Health


Kevin Wasserstein, Neurotechnology Innovations Translator

Collaborations Between Japan and Silicon Valley Click here to play audio
There is growing interest from Japan to invest in and collaborate with US Medtech companies, venture funds and incubators, many of which are located in Silicon Valley. For the first time in many years the major Japanese trading companies are focusing on reenergizing their Medtech businesses. This represents a major opportunity for Silicon Valley start-ups to seek investments from and partnerships with Japanese businesses. Join this panel to learn about the ways in which Japan and Silicon Valley start-ups are collaborating to finance and develop advanced medical technologies.


Jack Moorman, US-Japan MedTech Frontiers


James Hong, Solinas Medical


Masa Ishii, AZCA Venture Partners, Inc.


Ken Toda, Century Medical, Itochu


Takuya Yano, Development Bank of Japan

Obtaining Reimbursement in the Changing Healthcare System Click here to play audio
Yesterday a generation of companies found huge success by bringing less invasive solutions to address each of the major markets in healthcare.  Today less invasive solutions are just not enough.  CEOs must understand that product adoption requires that companies develop products that drive quality up at the right cost. Accelerating the adoption of important new but unreimbursed medical devices requires a company to test their devices, define and measure outcomes, clarify the concept of value and explore paths to reimbursement. Join this panel to understand the puzzle of reimbursement and what it takes to get providers to adopt your product solutions.


Casey McGlynn, Wilson Sonsini Goodrich & Rosati


Nancy Kolb, Formerly at Uroplasty, Inc.


Ted Lamson, NeoTract, Inc.


Jerry Stringham, Medical Technology Partners


10:30 – 10:50 a.m.


10:50 – 11:50 a.m.

Breakout Session 2

Corporate Investors and Buyers Click here to play audio
Meet corporate investors from two large Medtech consolidators. Learn about the interests of each company in corporate partnering with emerging Medtech companies. Hear about the typical arrangements corporate acquirers like to structure and the therapeutic areas of interest to them today. This panel will also include information on how these arrangements can come undone and ways to make sure the deal ends up as a win-win transaction that will benefit management, investors and the acquirers.


Marty Waters, Wilson Sonsini Goodrich & Rosati


Renee Compton Ryan, Johnson & Johnson


Pete Shagory, CONMED Corporation

New Corporate Deal Models Click here to play audio
The Medtech consolidators have a problem.  They need to introduce important new products to continue to grow their business. Unfortunately, internal innovation is expensive and unpredictable. The Medtech start-up that understands this need and identifies important clinical solutions can succeed in this rough and tumble marketplace.  Join a panel of business development professionals from the Medtech consolidators as they discuss what large companies are looking for today and how evolving deal structures can benefit both buyer and seller.


Steve Levin, Innovation in Medtech


Fred Aslan, Adavium Medical


Hanson Gifford, The Foundry


Bruce Roberts, RM Global Partners LLC


Thierry Thaure, Cephea Valve Technology

Off-Label Promotion vs. Free Speech Click here to play audio
It certainly seems odd that speaking the truth can violate the law. Yet the Food and Drug Administration takes the position that when it approves a drug or device for a particular treatment, the manufacturer of that product cannot promote it for other uses even if those statements are true.  But this FDA policy has been called into question in a number of recent decisions.  Join a panel of experts as we explore the FDA’s prohibition of off label promotion and the implications of these recent “Free Speech” cases for device manufacturers.


David Hoffmeister, Wilson Sonsini Goodrich & Rosati


Charles Andres, Wilson Sonsini Goodrich & Rosati


Jon Nygaard, Wilson Sonsini Goodrich & Rosati

Hiring and Compensating the CEO Click here to play audio
Let’s talk about executive compensation for the Medtech CEO. Join a group of compensation experts as they look at recent trends and emerging best practices in compensation. Participate in a discussion of current salary, stock and bonus structures for management. Learn about the structure and pitfalls associated with carve out plans and innovative ways to provide management teams compensation for successful exits. Finally, learn what executive recruiters are looking for in a resume and how networking skills can help you land your next great job.


Donna Petkanics, Wilson Sonsini Goodrich & Rosati


Scott McCall, Wilson Sonsini Goodrich & Rosati


Gale Richards, BioQuest


Jody Thelander, J. Thelander Consulting


11:50 a.m. – 12:10 p.m.


12:10 – 1:10 p.m.

Breakout Session 3

Commercialization Strategies Click here to play audio
Historically building a large sales force to sell important breakthrough Medtech products has been the recipe for a successful acquisition. But has the world changed? What new kind of sales structures will be required in the future? Will sales forces get smaller as the buy decision is increasingly made by the finance department instead of the doctor? Join a panel of CEOs who have launched new products, built sales organizations and created very successful businesses in the past as they look at the evolving commercialization strategies required for product adoption and discuss the issues that keep them up at night.


Nikolas Kerr, Kerr Consulting Group


Tony Recupero, Catalyst Performance Advisors, LLC


David Amerson, NeoTract, Inc.


Greg Casciaro, Cardiac Dimensions Inc.


Alex DiNello, Relievant


Karen Talmadge, Nabu Health Care Consulting

Asian Funding Strategies Click here to play audio
Join a panel of experienced Asian investors who can assist you in funding your company, and listen to US CEOs who have established a business unit of their company in China. Learn how these transactions are structured and the factors that draw Asian investors to the US and US entrepreneurs to China.


Elton Satusky, Wilson Sonsini Goodrich & Rosati


Mike Carusi, Lightstone Ventures


Mike Gertner, Kona Medical, Inc.


Ty Hu, InnoVentures Medical Accelerator


Nick Pliam, DeCheng Capital


Forest Xu, Virtus Inspire Ventures

The Israeli Medtech Revolution Click here to play audio
Israel has long been an innovation leader in the development of advanced Medical Devices.  The country has a strong start-up focus, leading academic technical and clinical centers, an abundance of engineering talent, and a unique incubator program which provides seed funding for early stage companies.  Israel and the U.S. have a close collaboration as many of the Israeli companies open offices in the U.S. to market and sell their products.  Join a panel of experts as we explore the Israeli medtech industry and its relationship with the United States.


Steve Levin, Innovation in Medtech


Efi Cohen-Arazi, Rainbow Medical


Oded Cohen, UpRight Technologies Ltd.


Talia Cohen, California Israel Chamber of Commerce


Galit Zuckerman, Medasense Biometrics Ltd.


1:10 – 2:40 p.m.

Lunch Interview
Join David Cassak in a conversation with Josh Makower, General Partner responsible for all MedTech and Healthcare investing at New Enterprise Associates (NEA). NEA is one of the largest and oldest venture firms in the United States and a major player in funding Medtech companies. Learn about the criterion NEA uses in selecting new investments and how they evaluate companies seeking funding in this sector.


David Cassak, The MedTech Strategist


Josh Makower, NEA


2:40 – 3:40 p.m.

Breakout Session 4

Spotlight on Technology—Valves Click here to play audio
Perhaps the most important new medtech products introduced during the last decade have been the string of percutaneous valve products which have revolutionized the Heart Valve Market. Starting with Edwards acquisition of Percutaneous Valve Technologies and followed shortly thereafter by Medtronic’s CoreValve acquisition, this marketplace has been a major focus of innovation.  The recent round of acquisitions and corporate partnerships in 2015 have moved from Atrial Valve Replacement to Mitral Valve Replacement, but the innovation continues in valve repair and several ancillary markets.  Join the discussion with a KOL, start-up executive, analyst, and business development executive as we look at the future of innovation in this space.


Casey McGlynn, Wilson Sonsini Goodrich & Rosati


Don Bobo, Jr., Edwards Lifesciences


Rob Michiels, CONSILIUM Associates LLC


Martin Rothman, Medtronic Vascular


Brooks West, Piper Jaffray

IPOs and Corporate Buyouts Click here to play audio
The pace of M&A activity in the Medtech sector continues at a solid pace. Medtech consolidators have been busy exercising buyout options they put in place in prior years, while a growing number of Medtech companies have been completing mergers on the eve of regulatory approval or soon after launching their products in the U.S. On the IPO front, a substantial number of companies have filed for and an impressive number have completed IPOs during this last year. For Medtech companies with growing sales, it seems like the window for IPOs continues. With this as a background, our panel will explore recent M&A and IPO transactions with a goal of understanding what a company needs to have in place to successfully complete these transactions.


Phil Oettinger, Wilson Sonsini Goodrich & Rosati


Andrew Cleeland, TMVR (formerly Twelve Inc.) at Medtronic


Rakesh Mehta, J.P. Morgan


Eric Shiozaki, Novo Ventures

The Role of IP Due Diligence in Corporate Finance 
Patent diligence is an inevitable part of all financings and public offerings. For companies, preparation is essential to present a positive picture to investors and avoid misunderstandings that can be hard to correct later. For investors, having a realistic perspective on the practical value of patent protection and the true risks of third party patents is equally important. This panel will describe efficient approaches to diligence and practical ways for dealing with perceived risks which arise during the diligence process. Differences between Europe and the U.S. will be considered.


Jim Heslin, Wilson Sonsini Goodrich & Rosati


Eric Bell, Spring Rock Ventures


Mir Imran, InCube Ventures


Gwen Watanabe, Teleflex


3:40 – 4:00 p.m.


4:00– 5:00 p.m.

MedTech Innovator 2016 Click here to play audio
Four early stage companies will be selected from hundreds of applications to present their pitch to a panel of judges. These companies will vie for the title of MedTech Innovator. The judges will evaluate the presentations and give feedback to each of the companies that present, and the audience will select the winner using electronic polling. The winner will be profiled in an upcoming issue of the MedTech Strategist and will go on to compete as a semi-finalist at the MedTech Innovator finals at AdvaMed2016.


Paul Grand, RCT Ventures


Daniel Kraft, Singularity Univ, Exponential Medicine & RegenMed Systems


Albert Lauritano, Strategic Technology Partnerships, BD


Jan B. Pietzsch, Wing Tech Inc.


Renee Compton Ryan, Johnson & Johnson


5:00 – 6:30 p.m.

Venture Capital Uncorked
Join Wilson Sonsini Goodrich & Rosati for wine tasting after the conference. We will be sampling wines from various wineries, with venture capitalists serving as your sommeliers for the event. This is your chance to try some great wine and learn a little bit more about what each of our local venture firms are looking for in their next deal. It's a great pairing — wine with a venture capital twist.